

Focused on Growth and Innovation

"Patients are at the heart of what we do"

Investor presentation

October 26, 2022



Table of contents

- Executive summary
- Portfolio
 - Antifungal
 - Cresemba® (isavuconazole)
 - Antibiotic
 - Zevtera® (ceftobiprole)
- Financials & Outlook
- Appendix



2



Executive summary



Experienced leadership team



(basilea)

4

At a glance

- Focus on the treatment of serious bacterial and fungal infections
- Recognized ability to establish and manage partnerships in both the development and commercial phase
- Cresemba[®] and Zevtera[®] two revenue generating hospital anti-infective brands
- Commercial products complemented by programs which are in an earlier stage of development
- On track to achieve sustainable profitability in 2023
- Listed on SIX Swiss Stock Exchange, SIX: BSLN
- Located in the Basel area life sciences hub, Switzerland




Uniquely positioned to create sustainable value in an area of increasing unmet medical need

Cresemba

- > USD 352 mn global in-market sales in 12-months to June 2022
- Recently launched in China and regulatory decision expected in Japan in H2 2022
- 22.5% royalty income growth in H1 2022

Royalty income growth (in CHF mn)



Note: Consolidated figures in conformity with U.S. GAAP; rounding applied consistently

Zevtera

- Successful ERADICATE and TARGET phase 3 studies
- Preparing to access the U.S. market: NDA submission expected around year-end
- U.S. represents ~ 80–90% of global commercial potential for branded MRSA hospital antibiotics

Portfolio

- A number of preclinical programs, including a CARB-X funded antibiotic against multi-drug resistant Gram-negative bacteria and a potential first-in-class broad-spectrum antifungal
- Focus on external sourcing of additional clinical and preclinical anti-infective compounds


Potential for sustainable growth and value creation based on commercialized brands and innovative pipeline

	Products / Product candidates / Indication	Preclinical	Phase 1	Phase 2	Phase 3	Market
Antifungals	Cresemba [®] (isavuconazole) Invasive aspergillosis and mucormycosis (U.S. and EU and several other countries)					
	Deep-seated mycoses, including invasive aspergillosis, chronic pulmonary aspergillosis (CPA), mucormycosis and cryptococcosis (Japan)					
	First-in-class broad-spectrum antifungal program ¹ Difficult-to-treat mold infections					
Antibiotics	Zevtera [®] (ceftobiprole)					
	Hospital- and community-acquired bacterial pneumonia (HABP, CABP) (major European and several non-European countries)					
	Acute bacterial skin and skin structure infections (ABSSSI) TARGET study ²					
	Staphylococcus aureus (MSSA/MRSA) bacteremia ERADICATE study² (bloodstream infections) ERADICATE study²					
	DXR inhibitor program³ CARB-X Infections caused by multi-drug resistant Gram-negative bacteria					
	Internal & external innovation	Research	Development			

1 Licensed from FCCDC

2 Studies to support U.S. NDA. Phase 3 program is funded in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA).

3 CARB-X's funding for this project is sponsored by Cooperative Agreement Number IDSEP160030 from ASPR/BARDA and by awards from Wellcome Trust and Germany's Federal Ministry of Education and Research. The content is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders.



8

The company we keep — established strong partnerships




Antifungal Cresemba® (isavuconazole)

Invasive mold infections

The market — Invasive fungal infections


- Severe, potentially life-threatening infections mainly affecting immunocompromised patients
- An important cause of morbidity and mortality in cancer patients undergoing intensive chemotherapy regimens
- Rising number of immunocompromised patients (cancer and transplantations) driving therapeutic demand
- Mucorales infections on the rise doubled from 2000 to 2013
- Limitations of current therapies (spectrum of activity, toxicity, effective plasma levels) drive the need for new agents

Mortality rates for invasive fungal infections**



**Kullberg/Arendrup *N Engl J Med* 2015, Baddley *Clin Infect Dis* 2010, Roden *Clin Infect Dis* 2005, Greenberg *Curr Opin Infect Dis* 2004

Cresemba continues strong in-market sales uptake




MAT: Moving annual total; Source: IQVIA Analytics Link, June 2022

(basilea) Focused on Growth and Innovation

Cresemba has become the market leader in the U.S. in terms of value

 Consistently increased market share among best-in-class antifungals* since launch to 36% by June 2022**



**Market share based on MAT Q2 2022, in-market sales reported as moving annual target (MAT) in U.S. dollar; rounding consistently applied. Source: IQVIA Analytics Link, June 2022

* Best-in-class antifungals: Cresemba (isavuconazole), posaconazole, voriconazole, AmBisome, anidulafungin, caspofungin, micafungin

(basilea) Focused on Growth and Innovation


Confidential/proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution

Sales of best-in-class antifungals* by product

USD 3.1 bn sales (MAT Q2 2022)

Significant potential to increase Cresemba® (isavuconazole) global market share

- Anticipated to be launched in ~70 countries by end-2022
- Exclusivity through 2027 in the U.S. and potential pediatric exclusivity extension to 2027 (from 2025) in the EU



* Best-in-class antifungals: Cresemba (isavuconazole), posaconazole, voriconazole, AmBisome, anidulafungin, caspofungin, micafungin

(basilea) Focused on Growth and Innovation

MAT: Moving annual total; Source: IQVIA Analytics Link, June 2022, rounding consistently applied

Confidential/proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution 14

Cresemba — Differentiated by spectrum, safety and tolerability

- Broad spectrum of activity against molds, including emerging molds (mucorales)
- Consistent plasma levels
- Statistically fewer drug-related adverse events and treatment-emergent adverse events (liver, skin, eye) in invasive aspergillosis patients vs. voriconazole in SECURE phase 3 study
- Can be administered without restriction in patients with renal impairment

- Manageable drug-drug interaction profile
- Once daily maintenance dose, i.v./oral treatment
- ECIL-6 guideline: Cresemba[®] recommended for the first-line treatment of invasive aspergillosis in leukemia and hematopoietic stem cell transplant patients. ECIL states that isavuconazole is as effective as voriconazole with a better safety profile.

Antibacterial Zevtera® (ceftobiprole)

Severe bacterial infections

Zevtera[®] — An introduction

- Broad-spectrum hospital anti-MRSA cephalosporin (including Gram-negative bacteria)
 - Rapid bactericidal activity
 - Potential to replace antibiotic combinations
 - Efficacy demonstrated in phase 3 clinical studies in SAB, ABSSSI and pneumonia^{1, 2, 3}
 - Low propensity for resistance development¹
 - Safety profile consistent with the cephalosporin class safety profile, demonstrated in both adult and pediatric patients^{1, 2, 3, 4}
- Marketed in selected countries in Europe,
 Latin America, the MENA-region and Canada
- U.S. NDA submission expected around year-end 2022

Approved in major European countries & several non-European countries for both hospitalacquired bacterial pneumonia (HABP), excluding ventilator-associated pneumonia (VAP), and community-acquired bacterial pneumonia (CABP). Not approved in the U.S.

MENA: Middle East and North Africa


(basilea) Focused on Growth and Innovation



¹ Syed YY. Drugs. 2014;74:1523-1542 and Basilea data on file.

- ² Overcash JS et al. Clin Infect Dis. 2021;73:e1507-e1517.
- ³ Holland TL et al. IDWeek 2022, LB2302
- ⁴ Rubino CM et al. Pediatr Infect Dis J. 2021;40:997-1003.

The hospital anti-MRSA antibiotic market — A USD 2.7 bn market* with the U.S. being the most important region



* Vancomycin, linezolid, teicoplanin, daptomycin, tigecycline, telavancin, ceftaroline, dalbavancin, ceftobiprole, oritavancin and tedizolid (daptomycin and tigecycline are partial sales in the USA in IQVIA data)

MRSA: Methicillin-resistant Staphylococcus aureus; LOE: Loss of exclusivity; ROW: Rest of world; MAT: Moving annual total; Source: IQVIA Analytics Link, June 2022

(basilea) Focused on Growth and Innovation

Ceftobiprole — Strategy for accessing the U.S. market

- Planned U.S. NDA submission to be supported by:
 - Two successfully completed cross-supportive phase 3 studies under FDA Special Protocol Assessment (SPA)
 - Acute bacterial skin and skin structure Infections (ABSSSI)¹
 - 2. Staphylococcus aureus bacteremia (SAB)²



- Additionally explore the possibility of gaining approval for CABP as a third indication
 - Phase 3 study in CABP previously completed³

- Phase 3 program largely funded by BARDA (~70% total program costs; up to USD ~136 mn)
- Qualified Infectious Disease Product (QIDP) designation extends U.S. market exclusivity to 10 years from approval
- Commercialization planned through partnership




¹ Overcash JS et al. Clin Infect Dis. 2021;73:e1507-e1517. (NCT03137173)
 ² Holland TL et al. IDWeek 2022, LB2302
 ³ Nicholson SC et al. International Journal of Antimicrobial Agents 2012 (39), 240-246

(basilea) Focused on Growth and Innovation

SAB – An area with high medical need

- Nearly 120,000 S. aureus bloodstream infections in the U.S. (in 2017)¹
- ERADICATE targets complicated SAB, characterized by concomitant or metastatic infections such as bone, joint or heart valve infections; persistent bacteremia; or bacteremia in patients on dialysis
- Substantial morbidity and approximately 20%
 30-day mortality²
- Limited antibiotic treatment options with only two approved treatments for SAB in the U.S. that cover both MSSA and MRSA, i.e. vancomycin and daptomycin



Adapted from Edwards AM et al. Trends Microbiol. 2011;19:184-190.

¹ MMWR, 2019;68:214–219.

² Hamed K et al. Future Microbiol. 2020;15:35-48. MRSA: methicillin-resistant *Staphylococcus aureus* MSSA: methicillin-susceptible *Staphylococcus aureus*


basilea

Focused on Growth and Innovation

Confidential/proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution


Causes and consequences of SAB

SAB — Highest disease burden among bloodstream infections



- Circle areas reflect total number of deaths
- Color coding represents the risk of dying from the pathogen relative to a control

Adjusted Mortality OR



Adapted from: Verway M et al. J Clin Microbiol. 2022;60:e0242921.

(basilea) Focused on Growth and Innovation

ERADICATE — The largest phase 3 registrational study conducted in SAB


- ERADICATE is the largest phase 3 study conducted for registrational purposes of a new antibiotic treatment in Staphylococcus aureus bacteremia.
- The randomized, double-blind, multicenter phase 3 study was a global study performed in 60 study centers in 17 countries from August 2018 to March 2022.
- 390 patients were randomized to ceftobiprole or daptomycin, with or without intravenous aztreonam for coverage of Gram-negative pathogens, for up to 42 days of treatment.
- Patient characteristics in the 387 patients included in the modified intent-to-treat (mITT) population were balanced between the treatment groups.

ERADICATE — Study design

- Patients age \geq 18 years
- SAB based on ≥1 positive blood culture within 72 h of randomization
- Confirmed or suspected complicated SAB or definitive right-sided infective endocarditis

Screening assessments

• Requirement for \leq 42 days of antibacterial treatment




Adapted from Hamed K et al. Future Microbiol. 2020;15:35-48

*Ceftobiprole was administered 500 mg q6h on Day 1-8 and 500 mg q8h from Day 9 onwards. Daptomycin was administered at 6mg/kg up to 10 mg/kg q24h. Three patients in the ITT population were excluded from the modified intent-to-treat population (mITT): One patient was randomized but not dosed, and two patients did not have a positive S. aureus blood culture at baseline

(basilea) Focused on Growth and Innovation

Primary endpoint is achieved (DRC assessed overall success at PTE in mITT population)


% Patients with overall success at PTE




- Non-inferiority demonstrated based on the pre-defined non-inferiority margin of 15%
- Consistent results in key subgroups and various categories of underlying conditions:
 - MSSA or MRSA bloodstream infections at baseline
 - Skin and skin structure infections
 - Abdominal abscesses
 - Chronic dialysis
 - Septic arthritis
 - Osteomyelitis
 - Definite right-sided infective endocarditis
 - Patients with persistent SAB

DRC: Data review committee; PTE: Post-treatment evaluation visit at 70 days post-randomization *Cochran-Mantel-Haenszel (CMH) weights method adjusted for actual stratum (dialysis status and prior antibacterial treatment use)

Secondary efficacy outcomes are similar





* Between-group difference (95%CI) of ceftobiprole minus daptomycin (± aztreonam), adjusted for actual stratum (dialysis status and prior antibacterial treatment use) using Cochran-Mantel-Haenszel weights method. CE: Clinically evaluable population.

% Patients with respective outcome at PTE

(basilea) Focused on Growth and Innovation

ERADICATE — Further results

- Median time to Staphylococcus aureus bloodstream clearance
 - MSSA: 3 days with ceftobiprole and 4 days with daptomycin
 - MRSA: 5 days for both ceftobiprole and daptomycin
- Emergence of resistance under treatment was observed in three patients on daptomycin.
 No emergence of resistance under treatment was observed with ceftobiprole
- Observed ceftobiprole safety and tolerability profile is consistent with previous phase 3 studies and the postmarketing experience
- Ceftobiprole was well tolerated and overall rate of adverse events similar between the ceftobiprole and daptomycin groups; gastrointestinal side effects were more frequent with ceftobiprole (mainly driven by mild to moderate nausea)

Zevtera — Place in therapy

- Ceftobiprole is an excellent treatment option in difficult-to-treat patients presenting to the hospital with severe infections, especially when the clinician suspects involvement of Gram-positive pathogens including Staphylococcus aureus
- For these patients ceftobiprole provides a single agent first-line bactericidal broad-spectrum therapy with proven efficacy in SAB, ABSSSI and CABP, enabling to treat these vulnerable patients effectively early in their disease to achieve recovery
- Ceftobiprole is differentiated versus competitors in various clinically important aspects, including:
 - The strong, bactericidal activity against MSSA and MRSA
 - A robust Gram-negative coverage
 - Efficacy demonstrated in pulmonary infections in phase 3 studies
 - The renal safety profile
 - The low propensity for resistance development



Financials & Outlook




Guidance — Sustainable profitability from FY 2023 expected

In CHF mn	FY 2023e	FY 2022e*	FY 2021
Cresemba & Zevtera related revenue	-	98 – 104	131.4
Royalty income	-	~ 59	53.2
Total revenue	-	116 – 122	148.1
Cost of products sold	-	21 – 24	24.1
Operating expenses	-30% vs. 2022	~ 110	122.9
Operating (loss)/profit	> 0	(10 – 15)	1.2
Net cash used in operating activities	Cash flow positive	0 – 5	32.0

Decrease in Cresemba & Zevtera related revenue 2022 vs. 2021 due to lower expected milestone payments

Net cash used in operating activities



Key milestones

Product	H1 2022	H2 2022	
Coftobiorala (Zautora)	Completed patient enrolment in phase 3 SAB study (ERADICATE)		
Ceftobiprole (Zevtera)	Positive results of phase 3 SAB study (ERADICATE)	U.S. NDA submission (around year-end)	
	Marketing approvals in China	Marketing approval in Japan	
Isavuconazole (Cresemba)	Marketing approvals in China	Launched in ~70 countries	

Complete transactions of oncology assets

Increasing Cresemba & Zevtera revenue


Advancement of preclinical anti-infective assets

In-licensing of anti-infectives

Appendix

Financial summary, in CHF mn (1/2)






Note: Consolidated figures in conformity with U.S. GAAP; rounding applied consistently

(basilea) Focused on Growth and Innovation

Financial summary, in CHF mn (2/2)






Note: Consolidated figures in conformity with U.S. GAAP; rounding applied consistently, *Cash, cash equivalents, restricted cash and investments

Confidential/proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution

Cresemba royalty income growth reflects continued commercial success in key territories (in CHF mn)




Note: Consolidated figures in conformity with U.S. GAAP; rounding applied consistently

(basilea) Focused on Growth and Innovation

Significant sales of bestin-class antifungals in all major regions — Covered by our partnerships

USD 3.1 bn sales of best-in-class antifungals* (MAT Q2 2022)



* Best-in-class antifungals: Cresemba (isavuconazole), posaconazole, voriconazole, AmBisome, anidulafungin, caspofungin, micafungin

(basilea) Focused on Growth and Innovation

MAT: Moving annual total; Source: IQVIA Analytics Link, June 2022


Ceftobiprole — Positive phase 3 results reported in ABSSSI

Results showing non-inferiority of ceftobiprole to vancomycin plus aztreonam for the primary and secondary endpoints¹



Early clinical response at 48–72h after start of treatment (ITT population)

Patients with early clinical success at 48-72 hours (%)



ITT: intent-to-treat

Pre-defined limit of non-inferiority = lower limit of 95 % CI for difference > -10 %

¹ Overcash JS et al. Clin Infect Dis. 2021;73:e1507-e1517.

(basilea) Focused on Growth and Innovation

Confidential/proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution

Ceftobiprole — Positive phase 3 results reported in ABSSSI

Key topline study¹ results showing non-inferiority of ceftobiprole to vancomycin plus aztreonam for the primary and secondary endpoints




¹NCT03137173 ABSSSI: Acute bacterial skin and skin structure infections

(basilea) Focused on Growth and Innovation

Investigator-assessed clinical success at test-of-cure (TOC) 15-22 days after randomization (ITT, CE populations)

Patients with clinical success at the TOC visit (%)



CE: clinically evaluable; ITT: intent-to-treat

Confidential/proprietary information of Basilea Pharmaceutica International Ltd, Allschwil – not for distribution

38

Ceftobiprole key attributes for SAB treatment


- Advanced generation cephalosporin with broad spectrum bactericidal activity against Gram-positive organisms, including MRSA and MSSA, and Gramnegative organisms¹
- Efficacy demonstrated in phase 3 clinical studies in acute bacterial skin and skin structure infections, and pneumonia^{1,2}
- Superior activity profile in multiple in vivo models of serious infection compared to vancomycin and daptomycin³
- Low propensity for resistance development¹
- Established safety profile consistent with the cephalosporin class, demonstrated in both adult and pediatric patients^{1,2,4}

¹Syed YY. Drugs. 2014;74:1523-1542. ²Overcash JS et al. Clin Infect Dis. 2021:73:e1507-e1517. ³Tattevin P et al. Antimicrob Agents Chemother. 2010;54:610-613. ⁴Rubino CM et al. Pediatr Infect Dis J. 2021:40:997-1003.

Focused on Growth and Innovation

(basilea)





Organism titers in cardiac vegetations, spleens and kidneys of untreated and antibiotic treated rabbits infected with MRSA³

Glossary

—	ABSSSI:	Acute bacterial skin and skin structure infections
—	BARDA:	Biomedical Advanced Research and Development Authority
—	CABP:	Community-acquired bacterial pneumonia
—	CE:	Clinically evaluable
—	CPA:	Chronic pulmonary aspergillosis
—	CARB-X:	Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator
—	DRC:	Data review committee
—	HABP:	Hospital-acquired bacterial pneumonia
-	ITT:	Intent-To-Treat
-	i.v.:	Intravenous
_	mITT:	Modified intent-to-treat
_	MSSA:	Methicillin-susceptible Staphylococcus aureus
-	MRSA:	Methicillin-resistant Staphylococcus aureus
_	NDA:	New drug application
-	OR:	Odds ratio
-	PTE:	Post-treatment evaluation
-	QIDP:	Qualified Infectious Disease Product
-	SAB:	Staphylococcus aureus bacteremia
-	SPA:	Special Protocol Assessment
-	U.S. GAAP:	United States Generally Accepted Accounting Principles
-	VAP:	Ventilator-associated pneumonia

(basilea)

40

Disclaimer and forward-looking statements

This communication, including the accompanying oral presentation, contains certain forward-looking statements, including, without limitation, statements containing the words "believes", "anticipates", "expects", "supposes", "considers", and words of similar import, or which can be identified as discussions of strategy, plans or intentions. Such forward-looking statements are based on the current expectations and belief of company management, and are subject to numerous risks and uncertainties, which may cause the actual results, financial condition, performance, or achievements of Basilea, or the industry, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the uncertainty of pre-clinical and clinical trials of potential products, limited supplies, future capital needs and the uncertainty of additional funding, compliance with ongoing regulatory obligations and the need for regulatory approval of the company's operations and potential products, dependence on licenses, patents, and proprietary technology as well as key suppliers and other third parties, including in preclinical and clinical trials, acceptance of Basilea's products by the market in the event that they obtain regulatory approval, competition from other biotechnology, chemical, and pharmaceutical companies, attraction and retention of skilled employees and dependence on key personnel, and dependence on partners for commercialization of products, limited manufacturing resources, management's discretion as to the use of proceeds, risks of product liability and limitations on insurance, uncertainties relating to public health care policies, adverse changes in governmental rules and fiscal policies, changes in foreign currency and other factors referenced in this communication. Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forwardlooking statements. Basilea disclaims any obligation to update any such forward-looking statements to reflect future events or developments, except as required by applicable law.



Focused on Growth and Innovation

Hegenheimermattweg 167b 4123 Allschwil Switzerland

info@basilea.com www.basilea.com

All rights reserved. © 2022 Basilea Pharmaceutica International Ltd, Allschwil